Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support

Stock Track

Jul 06

SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.

The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.

Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1171774118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171774118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171774118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171774118","market":"sg","top_or_hot":-1,"title":"Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support","media":"Stock Track","content":"<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | SBP GROUP Soars 5.49% Intraday on Drug Pipeline Progress and Favorable Policy Support\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-06 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.</p><p>The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.</p><p>Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1171774118","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171774118","pubTimestamp":1783302443,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"股票轨迹|SBP集团盘中大涨5.49%药物管线进展及政策利好支持","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"SBP GROUP's stock surged 5.49% during intraday trading on Monday, reflecting strong investor optimism toward the pharmaceutical company.The rally appears driven by positive developments in the company's drug pipeline, including the recent acceptance of a New Drug Application for ropivacaine hydrochloride sustained-release solution by China's National Medical Products Administration. This follows other recent pipeline milestones such as the NDA acceptance for tecotabart vedotin targeting gastric cancer and marketing approval for Peceleganan Spray for wound infections.Additionally, the broader innovative pharmaceutical sector is benefiting from supportive policy developments, with China's National Healthcare Security Administration reporting a 92% pass rate for innovative drug inclusion in medical insurance catalogs, representing an 8 percentage point year-over-year improvement and demonstrating continued policy support for innovative medicines.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}